ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ORIC Pharmaceuticals, a clinical stage oncology company, announced participation in two investor conferences in February 2021. The Guggenheim Healthcare Talks 2021 Oncology Day features a virtual fireside chat on February 11 at 1:00 p.m. ET, while the LifeSci Partners Precision Oncology Day will host investor meetings on February 17. A live webcast of the fireside chat will be available on their website for 90 days post-event. ORIC focuses on developing therapies addressing cancer resistance mechanisms, with notable candidates including ORIC-101, ORIC-533, ORIC-944, and ORIC-114.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:

• Guggenheim Healthcare Talks 2021 Oncology Day – Participating in a virtual fireside chat on February 11, 2021 at 1:00 p.m. ET/10:00 a.m. PT; and
  
  
• LifeSci Partners Precision Oncology Day – Hosting virtual investor meetings on February 17, 2021.
  

A live webcast of the fireside chat will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com.

Investor Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

What are the upcoming events for ORIC Pharmaceuticals in February 2021?

ORIC Pharmaceuticals will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11 at 1:00 p.m. ET and host investor meetings during the LifeSci Partners Precision Oncology Day on February 17.

Where can I watch the ORIC Pharmaceuticals webcast?

The live webcast for ORIC Pharmaceuticals' fireside chat can be accessed through the investor section of their website, available for 90 days after the event.

What is ORIC-101 and its significance in cancer treatment?

ORIC-101 is a potent small molecule antagonist of the glucocorticoid receptor, targeting resistance in various solid tumors and currently in Phase 1b trials.

What other product candidates is ORIC Pharmaceuticals developing?

In addition to ORIC-101, ORIC Pharmaceuticals is developing ORIC-533, ORIC-944, and ORIC-114, targeting various mechanisms of cancer resistance.